Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Eli Lilly and Company
LLY
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $1.1T
$1,211.38
▲ +1.65%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$623.78 - $1,238.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 52.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Diversified blockbuster portfolio with multiple revenue-generating franchises across high-demand therapeutic areas
- Strong R&D capabilities and clinical pipeline generating innovative treatments with premium pricing power
- Established market presence and brand recognition in diabetes and oncology, creating customer loyalty and switching costs
- Regulatory expertise and manufacturing scale enabling rapid commercialization of new therapies globally
Bear Case
2 risks
- Low volatility (beta 0.5).
- Growth premium of 2.5x vs Large Cap Pharma peers. Elevated but may be justified by growth trajectory.
Growth
Stable outlook
Rising global prevalence of diabetes and obesity driving demand for innovative therapies
Value
Growth premium of 2.5x vs Large Cap Pharma peers. Elevated but may be justified by growth trajectory.
Momentum
Hot
+27.4% over 3m
Quality
Excellent
High-growth business (47% revenue growth, 84% gross margin). Profitable with strong growth momentum.
Dividend
Modest
0.54% yield
Smart-money signal
Who's buying LLY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 29, 2026
APR 30, 2026
Reported EPS of $8.55 vs $6.97 consensus (+22.7% surprise). Revenue of $19.8B vs $17.8B expected (+11.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+22.7%
Next: Apr 29, 2026
Revenue trend · last 8Q
—
—
+45%
+45%
+38%
+54%
+43%
+56%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$11.3B
$11.4B
$13.5B
$12.7B
$15.6B
$17.6B
$19.3B
$19.8B
Margins · last 8Q
Gross
81.9%
Operating
44.7%
Profit
37.4%
Wall Street consensus
14 analysts · 93% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
93%
Hold
0%
Sell
7%
Median Price Target
$1,327.00
▲ +9.5% vs $1,211.38
Latest: Cantor Fitzgerald · Jun 22, 2026
6 analysts covering